Why the study?
Does AAV-VEGF gene therapy improve LV function and strain in a swine model of reperfused myocardial infarction?
Population
Swine model of reperfused myocardial infarction (n=12 analyzed; 6 treated, 6 controls)
Comparison
Cardiac-specific adeno-associated viral… vs Control animals
Design
Preclinical
Follow-up
8 weeks
Authors
Loading...
Preserves LVEF in swine reperfused MI; leaves open translation of AAV-VEGF gene therapy to human infarction.
Does AAV-VEGF gene therapy improve LV function and strain in a swine model of reperfused myocardial infarction?
AAV-VEGF gene therapy preserves ejection fraction and improves regional myocardial strain and wall thickening in a swine model of reperfused myocardial infarction.
Jacquier et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: